Latest News
-

Huntington's Disease Therapeutics Conference 2014: day 3
Biomarkers and preparing for trials: the third & final day of the 2014 Huntington's Disease Therapeutics Conference
-

Huntington's Disease Therapeutics Conference 2014: day 2
Cells, circuits and systems: day 2 of the 2014 HD Therapeutics conference
-

Huntington's Disease Therapeutics Conference 2014: day 1
HDBuzz reports from the opening day of science sessions at the 2014 HD Therapeutics Conference in Palm Springs.
-

Prana announces results of Reach2HD trial of PBT2 for Huntington's disease
Results are in for a clinical trial testing the drug PBT2 for HD. Are the claims in the announcement justified?
-

Does high-dose creatine "slow the onset" of Huntington's Disease?
A new study claims that high-dose creatine "slows the onset of Huntington Disease". How much hope and how much hype?
-

Joint HDBuzz Prizewinner: Yeast studies suggest a new way to protect cells from 'oxidative damage'
Researchers identify Gpx1, a protein that may be protective in HD. An existing drug can mimic its antioxidant effect.
-

Joint HDBuzz Prizewinner: Pennies for your neurons — copper’s bad influence on Huntington’s disease
There is copper in your brain! Check out how copper and the Huntington’s disease protein are partners in crime.
-

Could a 'brain shuttle' get Huntington's disease drugs to where they're needed?
Roche's 'brain shuttle' sneaks drugs past the blood-brain barrier. Could it work for HD gene silencing drugs?
-

Is a new Huntington’s Disease drug study on the right Trk?
A recent HD animal study reveals that a small molecule drug could be an effective “Trk” to target for HD therapeutics
-

DNA shutdown proteins in Huntington's disease: More than meets the eye
Blocking HDAC4 improves Huntington's disease-related problems in cells and mice – but in a surprising way
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial
Previously featured
-
Split Between Two Worlds: The Psychological Challenges for People at Risk of Huntington’s Disease
-
Putting it in print: oral drug branaplam lowered huntingtin, but safety concerns halted development
-
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease
-
Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin
-
January 2026: This Month in Huntington’s Disease Research
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
